Almirall and Simcere enter into a licensing agreement for IL-2-mu-Fc
Nanjing (China) and Barcelona (Spain), a global biopharmaceutical company focused on skin health, and Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Under the agreement,
